Cowen conference-031318-intro-slides-final-v2
- 1. Cowen and Company Health Care Conference Pfizer Oncology Andy Schmeltz Global President, Pfizer Oncology March 14, 2018
- 2. 2 Forward Looking Statements This presentation includes forward-looking statements about, among other things, Pfizers oncology in-line products and product candidates, including anticipated regulatory submissions, approvals, performance and potential benefits of Pfizer's oncology products and product candidates, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors that May Affect Future Results, as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (SEC) and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.
- 3. 3 Pfizer Oncology Growth Trajectory Growing in-line portfolio fueled by IBRANCE & XTANDI with potential for multiple launches on the horizon Curve is for illustrative purposes only *numbers for 2018-2020 reflect potential approvals and indications that are expected and may not materialize Opportunistic & Niche Growth & LeadershipMindset GLASDEGIB TALAZOPARIB DACOMITINIB LORLATINIB # Approved Medicines* 2 3 5 5 5 6 7 10 12 14 14 # Approved Indications* 3 5 7 8 8 9 11 17 20 21 28 E* E* E*2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Revenue$B
- 4. 4 A Rich Oncology Pipeline 1 Registration/Approvals: Only includes major regions (US, EU, JPN, CHN). * Additional clinical studies being conducted in other tumor types/segments and earlier phases. utomilumab (PF-05082566)(B164) 13 Phase 1 p-cadherin LP DART (PF-06671008)(B783) Angiogenesis Cell Signal Transduction / Oncogenic Driver Immunotherapy Cell Cycle & Metabolism Antibody Drug Conjugate Therapeutic Vaccine VBIR1 (PF-06753512)(B779) Anti-PD1 (PF-06801591)(B801) GD3 (PF-06688992)(B802) NG-HER2 (PF-06804103)(C054) BCMA CD3 (PF-06863135)(C107) UCART19 (PF-06883541)(C119) gedatolisib (PF-05212384)(B215) OX-40 (PF-04518600)(B060) PTK7 (PF-06647020)(B766) EGFR T790M (PF-06747775)(B797) Anti-MCSF (PD-360324)(A626) axitinib* RCC Adj 6 Phase 3 palbociclib* BC avelumab* NSCLC, Ovarian, RCC, Gastric, urothelial,SCCHN talazoparib* gBRCA mut mBC, CRPC enzalutamide* CRPC, HSPC lorlatinib ALK+ NSCLC 1L sunitinib RCC Adj (EU) dacomitinib* NSCLC (US,EU) lorlatinib ALK+ NSCLC 2L+ (US,EU,JPN) Registration1 bosutinib* CML 1L (EU) gemtuzumab ozogamicin AML (EU) enzalutamide* CRPC (US,EU) 6 Phase 2 4 glasdegib* AML (Fit & Unfit) avelumab* NSCLC, SCLC, H&N, Melanoma, TNBC, MCC talazoparib* CRPC sunitinib Pediatric GIST crizotinib* ALCL / Neuroblastoma (pediatric CRCs) as of February, 2018
- 5. 5 Partner with key stakeholders in the breast and prostate cancer communities Generate evidence for broader and optimal use Talazoparib: PARP inhibitior Avelumab: backbone PD-L1 therapy Identify and interrogate rational combinations with IO and non-IO mechanisms Innovative and meaningful patient engagement Advancing access via outcomes and real world evidence Redefining life with cancer Key Focus Areas IBRANCE & XTANDI* Pipeline Focused to Realize Our Vision To Be a Leader in Oncology by Speeding Cures and Accessible Breakthrough Medicines to Patients, Redefining Life with Cancer *Pfizer and Astellas jointly commercialize XTANDI in the United States
- 6. Q&A Andy Schmeltz Global President, Pfizer Oncology